No randomized controlled trial has compared vaginal progesterone and cervical cerclage directly for the prevention of preterm birth in women with a sonographic short cervix in the mid trimester, singleton gestation, and previous spontaneous preterm birth. We performed an indirect comparison of vaginal progesterone vs cerclage using placebo/no cerclage as the common comparator.
M
ost of the efforts to prevent preterm birth have been focused on the treatment of symptoms or signs of activation of the common pathway of parturition [1] [2] [3] [4] [5] (ie, increased uterine contractility, preterm cervical ripening, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] and/or membrane decidual activation [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] ). Although the detection of increased uterine contractility [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] has been the focus of clinicians and reproductive biologists for decades, emerging clinical [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] and laboratory-based evidence [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] suggests that focusing on the uterine cervix may yield approaches to identify the patient who is at risk for preterm delivery as well as interventions to prevent it. [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] A sonographic short cervix has emerged as a powerful predictor of preterm birth. [67] [68] [69] [70] [71] [72] [73] [74] [116] [117] [118] [119] [120] [121] [122] It is unlikely that this condition is due to a single cause; a multiple causation model of a sonographic short cervix has been proposed (eg, a short cervix is syndromic in nature). 75, 123, 124 Such model would have biologic, diagnostic, prognostic, and therapeutic implications. 3, 75 Indeed, patients may have a short cervix after diethylstilbestrol exposure in utero, [125] [126] [127] a cervical conization, [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] a loop electrosurgical excision procedure, [146] [147] [148] [149] [150] intrauterine infection/inflammation, [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] a decline in progesterone action, [162] [163] [164] [165] and the challenging condition clinically referred to as idiopathic cervical insufficiency. [166] [167] [168] [169] [170] [171] [172] [173] Three interventions have been proposed to treat patients with a sonographic short cervix: (1) vaginal progesterone administration, [101] [102] [103] [104] [105] (2) cervical cerclage for patients with a history of preterm birth, [174] [175] [176] [177] and (3) vaginal pessary. [97] [98] [99] Recently, a combination of vaginal progesterone and a pessary has been reported to be a successful method to reduce the rate of preterm delivery in twin gestations with a cervix of Ͻ25 mm. 178 Two independent randomized clinical trials 101, 104 and an individual patient data (IPD) metaanalysis showed that vaginal progesterone decreases the rate of preterm delivery and neonatal morbidity/mortality in women with a sonographic short cervix. 105 This is the case for patients with or without a history of preterm birth. 105 The placement of a cervical cerclage appears to be indicated in patients with acute cervical insufficiency, [179] [180] [181] [182] [183] [184] [185] [186] and perhaps, in some with a history of preterm birth and a sonographic short cervix of Ͻ25 mm. [174] [175] [176] [177] Thus, there appear to be 2 interventions that may reduce the rate of preterm delivery in patients with a history of preterm birth and a cervix of Ͻ25 mm: vaginal progesterone administration or a cervical cerclage.
Recently, 2 professional organizations have recommended that cerclage may be considered for the treatment of women with a singleton gestation, previous spontaneous preterm birth, and a cervical length Ͻ25 mm at Ͻ24 weeks of gestation. 187, 188 This recommendation was based mainly on an IPD metaanalysis of randomized controlled trials that show that cerclage is associated with a statistically significant reduction in the risk of preterm birth at Ͻ37, Ͻ35, Ͻ32, Ͻ28, and Ͻ24 weeks of gestation, and composite perinatal morbidity and mortality when compared with no cerclage. 176 However, another IPD metaanalysis demonstrated that vaginal progesterone administration to women with a sonographic short cervix (Յ25 mm) in the mid trimester significantly decreased the risk of preterm birth at Ͻ35, Ͻ34, Ͻ33, Ͻ30, and Ͻ28 weeks of gestation and composite neonatal morbidity and mortality when compared with placebo. 179 In addition, a subgroup analysis showed that vaginal progesterone was associated with a significant reduction in the risk of preterm birth at Ͻ33 weeks of gestation and composite neonatal morbidity and mortality in women with a short cervix (Յ25 mm), singleton gestation, and previous spontaneous preterm birth. 105 The availability of vaginal progesterone and cerclage for the prevention of preterm birth in women with a short cervix, singleton gestation, and previous spontaneous preterm birth could create a dilemma for physicians and patients about the optimal choice of treatment. 189 Thus far, there are no randomized controlled trials comparing vaginal progesterone and cerclage directly. In the absence of this evidence, indirect metaanalysis has emerged as an accepted and valid method for the comparison of competing interventions with the use of a common comparator. [190] [191] [192] [193] We performed an adjusted indirect metaanalysis to compare the treatment effects of vaginal progesterone vs cerclage in asymptomatic women with a cervical length Ͻ25 mm in the mid trimester, singleton gestation and previous spontaneous preterm birth for the prevention of preterm birth. Previously, we had conducted an IPD metaanalysis to evaluate the efficacy of vaginal progesterone vs placebo in patients with such characteristics. Then, the summary estimates and measures of uncertainty were used together with those reported in the IPD metaanalysis that evaluated cerclage vs no cerclage 177 to perform the adjusted indirect comparison metaanalysis.
MATERIALS AND METHODS
The study was conducted based on a prospectively prepared protocol and is reported with the use of the Preferred Reporting Items for Systematic reviews and Metaanalyses (PRISMA) guidelines for metaanalyses of randomized controlled trials 194 and suggested guidelines for IPD 195 and indirect metaanalyses.
ald technique), short cervix (short cervical length, short cervix, cervical shortening), and preterm birth (preterm, premature). Congress proceedings of international society meetings of maternal-fetal and reproductive medicine and international meetings on preterm birth, reference lists of identified studies, textbooks, previously published systematic reviews, and review articles were also searched. Experts in the field were contacted to identify further studies. No language restrictions were applied.
Study selection
We included randomized controlled trials in which asymptomatic women with a sonographic short cervix (cervical length, Ͻ25 mm) in the mid trimester, singleton gestation, and previous spontaneous preterm birth at Ͻ37 weeks of gestation were allocated randomly to receive vaginal progesterone vs placebo/no treatment or cerclage vs no cerclage for the prevention of preterm birth. Trials were included if the primary aim of the study was to (1) prevent preterm birth in women with such characteristics; or (2) prevent preterm birth in women with other characteristics, but outcomes were available for patients with a prerandomization cervical length Ͻ25 mm in the mid trimester, singleton gestation, and previous preterm birth. Trials were excluded if they (1) were quasirandomized, (2) evaluated the interventions in women with only multiple gestations, (3) evaluated vaginal progesterone in women with actual or threatened preterm labor, second trimester bleeding, or premature rupture of membranes, (4) evaluated the administration of progesterone in the first trimester only to prevent miscarriage, (5) assessed history-indicated cerclage (placed for the sole indication of poor obstetric history), physical examination-indicated cerclage (placed for second trimester cervical dilation), or compared different cerclage techniques or outpatient cerclage vs inpatient cerclage, (6) compared cerclage with 17␣-hydroxyprogesterone caproate, or (7) did not provide data for women with a cervical length Ͻ25 mm in the mid trimester, singleton gestation, and previous preterm birth.
All published studies that were deemed suitable were retrieved and reviewed independently by 2 authors (A.C-A. and R.R.) to determine inclusion. Disagreements were resolved through consensus.
Data collection
For the IPD metaanalysis that evaluated vaginal progesterone vs placebo, we contacted the corresponding authors to request access to the data. Authors were asked to supply anonymized data (without identifiers) about patient baseline characteristics, experimental intervention, control intervention, cointerventions, and prespecified outcome measures for every randomly assigned subject and were invited to become part of the collaborative group with joint authorship of the final publication. Data that were provided by the investigators were merged into a master database that had been constructed specifically for the review. Data were checked for missing information, errors, and inconsistencies by cross-referencing the publications of the original trials. Quality and integrity of the randomization processes were assessed by a review of the chronologic randomization sequence and pattern of assignment and the balance of baseline characteristics across treatment groups. Inconsistencies or missing data were discussed with the authors and corrections were made when deemed necessary. Finally, data were extracted for women with a cervical length Ͻ25 mm in the mid trimester, singleton gestation, and previous preterm births. A similar approach was used in the IPD metaanalysis by Berghella et al 177 that evaluated cerclage vs no cerclage.
Outcome measures
The prespecified primary outcome measures were preterm birth Ͻ32 weeks of gestation and composite perinatal morbidity and mortality (defined as the occurrence of any of the following events: respiratory distress syndrome, grade III/IV intraventricular hemorrhage, necrotizing enterocolitis, neonatal sepsis, bronchopulmonary dysplasia, or perinatal mortality). Secondary outcome measures included preterm birth at Ͻ37, Ͻ35, and Ͻ28 weeks of gestation, respiratory distress syndrome, necrotizing enterocolitis, grade III/IV intraventricular hemorrhage, neonatal sepsis, bronchopulmonary dysplasia, perinatal mortality, a composite neonatal morbidity outcome (defined as the occurrence of any of the above mentioned neonatal morbidities), birthweight Ͻ1500 g and Ͻ2500 g, and admission to the neonatal intensive care unit (NICU).
Assessment of risk of bias
The risk of bias in each included study was assessed by the use of the criteria recently outlined in the Cochrane Handbook for Systematic Reviews of Interventions. 197 Seven domains that are related to the risk of bias were assessed in each included trial because there is evidence that these issues are associated with biased estimates of treatment effect: (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data, (6) selective reporting, and (7) other bias. Review authors' judgments were categorized as "low risk" of bias, "high risk" of bias, or "unclear risk" of bias. The assessments considered the risk of material bias rather than any bias. Material bias was defined as a bias of sufficient magnitude to have a notable impact on the results or conclusions of the trial. The risk of bias in each included trial was assessed individually by 2 reviewers (A.C-A. and R.R.). Any differences of opinion regarding assessment of risk of bias were resolved by discussion.
Data extraction
Two authors (A.C-A. and R.R.) extracted data from each study on participants (inclusion and exclusion criteria, number of women and fetuses/infants in randomized groups, baseline characteristics, and country and date of recruitment), study characteristics (randomization procedure, concealment allocation method, blinding of clinicians, women and outcome assessors, completeness of outcome data for each outcome, which included attrition and exclusions from the analysis, and intention-to-treat analysis), details of interventions (aim, gestational age at trial entry, daily dose of vaginal progesterone and duration of treatment, cer-clage type and suture used, and cointerventions), and outcomes (number of outcome events/total number in women with a cervical length Ͻ25 mm, singleton gestation, and previous spontaneous preterm birth). Women with multiple gestations, no previous spontaneous preterm birth, or cervical length Ն25 mm were excluded. For studies that assessed cerclage, data on proportions and relative risks (RRs) with 95% confidence intervals (CIs) for each outcome measure were extracted from the IPD metaanalysis by Berghella et al. 177 Disagreements in extracted data were resolved by discussion among reviewers.
Statistical analysis
Statistical analyses were based on an intent-to-treat basis and included all randomly assigned women and their fetuses/infants. For studies that assessed vaginal progesterone, IPD were combined in a 2-stage approach in which outcomes were analyzed in their original trial, then summary statistics were combined with the use of standard summary data metaanalysis techniques to give an overall measure of effect (summary RR with 95% CI). 198 A similar approach was used in the IPD metaanalysis of trials that evaluated cerclage vs no cerclage. 177 Heterogeneity of the results among studies was tested with the quantity I 2 in the IPD metaanalysis of vaginal progesterone vs placebo 199 and the MantelHaenszel Q statistics in the IPD metaanalysis of cerclage vs no cerclage. I 2 values of Ն50% or a probability value of Ͻ .10 for Mantel-Haenszel Q statistics indicated a substantial level of heterogeneity. Fixed-effects models were used if substantial statistical heterogeneity was not present. Otherwise, random-effects models were used.
The number needed to treat for benefit or harm (with their 95% CIs) were calculated for the primary outcomes for which there was a statistically significant reduction or increase in risk difference based on control event rates in the included trials. 200 Publication and related biases were assessed visually by an examination of the symmetry of funnel plots and statistically by the use of the Egger test. 201 A probability value of Ͻ .1 was considered to indicate significant asymmetry.
The adjusted indirect comparison metaanalysis of vaginal progesterone vs cerclage was performed according to the most widely applied indirect comparison method by Bucher et al. 202 The Canadian Agency for Drugs and Technologies in Health 192 and others 190, 193, 203 have identified this method as the most suitable approach for performing indirect treatment comparisons of randomized controlled trials. In this method, the randomization of each trial is maintained, and the direct comparisons A vs B and C vs B with the common comparator link B are used to yield an indirect comparison of A vs C. Because vaginal progesterone and cerclage have been compared with placebo and no cerclage, respectively, indirect comparison was enabled by the "common" placebo/no cerclage arms. An extension of the Bucher approach was used to convert the Full-text articles assessed for eligibility (n = 32)
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Studies included in qualitative synthesis and metaanalyses (n = 9)
•Vaginal progesterone vs placebo (n = 4) 101, 104, 227, 228 •Cerclage vs no cerclage (n = 5) 113, 115, 174, 229, 230 Full-text articles excluded (n = 23)
Vaginal progesterone (n = 7)
•Cervical length was not measured or collected before randomization (n = 2) 204, 205 •Vaginal progesterone evaluated only in women with twin gestations (n = 2) 206, 207 •Vaginal progesterone evaluated in women with actual or threatened preterm labor (n = 3) [208] [209] [210] Cerclage (n = 16) •History-indicated cerclage vs no cerclage (n = 5) [211] [212] [213] [214] [215] •History-vs ultrasound-indicated cerclage (n = 3) [216] [217] [218] •Comparison of different cerclage techniques (n = 3) [219] [220] [221] •Cerclage evaluated only in women with multiple gestations (n = 2) 222, 223 •Quasirandomized and compared cerclage vs pessary (n = 1) 224 •Outpatient vs inpatient cerclage (n = 1) 225 •Cerclage vs 17α-hydroxyprogesterone caproate (n = 1) To examine the assumption of similarity of treatment effects, we investigated the effect of patient and trial characteristics on both direct and indirect comparison results with the use of sensitivity analyses. A predefined sensitivity analysis was conducted by excluding patients who received progesterone in trials that evaluated cerclage vs no cerclage and patients who received a cerclage in studies that compared vaginal progesterone with placebo to explore the impact of these cointerventions on the effect size for preterm birth and perinatal mortality. This analysis was performed because it is unclear whether the effects of progesterone and cerclage are additive in women with a short cervix, singleton gestation, and previous spontaneous preterm birth. An additional sensitivity analysis was planned to evaluate the effect of study quality on the main outcomes by the exclusion of trials with high risk of bias.
One author (A.C-A.) conducted all statistical analyses using Review Manager software (version 5.1.6; Nordic Cochrane Centre, Copenhagen, Denmark) for performing direct metaanalyses and Indirect Treatment Comparison software (version 1.0; Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada) to perform adjusted indirect comparison metaanalyses.
Informed consent was provided by the patients on enrollment in the each of the original trials. In this study, the data were not used for any other purpose other than those of the original trial, and no new data were collected. Therefore, informed consent specifically for this project was not considered necessary. This study was exempted for review by the HumanInvestigationsCommitteeofWayne State University. No patient identifiers were provided by any investigator.
RESULTS
Of the 5606 relevant citations that were identified, the abstracts were reviewed, and 32 studies were retrieved because they were considered potentially relevant to this indirect metaanalysis. Twenty-three studies were excluded ( Figure) . The remaining 9 trials met the inclusion criteria and provided data for 662 women with a cervical length of Ͻ25 mm at mid trimester, singleton gestation, and previous spontaneous preterm birth at Ͻ37 weeks of gestation. 101, 104, 113, 115, 174, [227] [228] [229] [230] Four studies evaluated vaginal progesterone vs placebo (158 women), 101, 104, 227, 228 and 5 studies evaluated cerclage vs no cerclage (504 women). 113, 115, 174, 229, 230 The main characteristics of studies that were included in this indirect comparison metaanalysis are presented in Table 1 . All 4 studies that evaluated vaginal progesterone were double-blind, placebo-controlled trials. 101, 104, 227, 228 None of the studies that assessed cerclage were double-blind. Seven trials (2 that evaluated vaginal progesterone 101, 104 and all 5 that evaluated cerclage 113, 115, 174, 229, 230 ) examined the interventions in women with a sonographic short cervix, 1 study evaluated the use of vaginal progesterone in women with a history of spontaneous preterm birth, 227 and the remaining study evaluated the use of vaginal progesterone in women with a previous spontaneous preterm birth, uterine malformations, or twin gestation. 228 Only 1 trial was designed specifically to evaluate the use of cerclage in women with a cervical length of Ͻ25 mm in the mid trimester, singleton gestation, and previous spontaneous preterm birth. 174 The primary outcome was preterm birth at Ͻ37 weeks of gestation for 1 trial, 228 Ͻ35 weeks of gestation for 2 trials, 113 ,174 Ͻ34 weeks of gestation for 2 trials, 101,115 Ͻ33 weeks of gestation for 2 trials, 104, 230 Յ32 weeks of gestation for 1 trial, 227 and gestational age at delivery for the remaining study. 229 Gestational age at cervical length screening varied between 14 and 25 weeks of gestation, although most studies performed screening at Ͻ25 weeks of gestation. 104, 113, 115, 174, [227] [228] [229] [230] Of the 4 trials that evaluated vaginal progesterone, 2 used gel (90 mg/d), 104 ,227 1 used capsules (200 mg/d), 101 and the other used suppositories (100 mg/d). 228 The treatment was initiated at 24 weeks of gestation in 2 trials, 101 ,228 between 20 and 23 weeks of gestation in 1 trial, 104 and between 18 and 22 weeks of gestation in the remaining study. 227 Two studies reported that participating women received study medication from enrollment until 34 weeks of gestation, 101, 228 and 2 studies reported that medication was given from enrollment until 36 6/7 weeks of gestation. 104, 227 In the study by Hassan et al, 104 5 women received an emergency cerclage. Among the 5 trials that evaluated cerclage, 4 used the McDonald procedure, 113, 115, 174, 229 and 1 used the Shirodkar technique. 230 Rescuecerclageinwomenwho were allocated to the no cerclage group was allowed in 3 studies based on physical examination 174 or based on ultrasonographic cervical changes. 115, 229 Prophylactic antibiotics and tocolytics were administered to most participating women in 3 studies, 115, 229, 230 whereas bed rest was recommended to all women who were recruited in 2 trials. 113, 115 In the trial by Owen et al, 174 99 women received 17␣-hydroxyprogesterone caproate, and 1 woman received vaginal progesterone. 231 All 9 studies that were included in the metaanalysis had adequate random sequence generation and allocation concealment, were free of selective outcome reporting, and had no obvious risk of other biases. In the 4 trials that evaluated vaginal progesterone, there was blinding of participants, health care providers, and outcome assessors. In the 5 trials that evaluated cerclage, study participants and health care providers were not blinded, and it was unclear whether outcome assessors were masked to intervention allocations after inclusion of patients into the study. However, we 
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judged that assessment and measurement of most outcomes that were included in our review are considered objective in nature and were not likely to be influenced by a lack of blinding in the studies that evaluated cerclage. All but one study 104 had adequate handling of incomplete outcome data. Overall, all 9 trials were considered to be at low risk of bias.
Direct comparisons
The use of either vaginal progesterone or cerclage in patients with a cervical length of Ͻ25 mm in the mid trimester, singleton gestation, and previous spontaneous preterm birth was associated with a significant reduction in the risk of preterm birth at Ͻ32 weeks of gestation (RR, 0.47; 95% CI, 0.24Ϫ0.91 for vaginal progesterone and RR, 0.66; 95% CI, 0.48Ϫ0.91 for cerclage) and composite perinatal morbidity and mortality (RR, 0.43; 95% CI, 0.20Ϫ0.94 for vaginal progesterone and RR, 0.64; 95% CI, 0.45Ϫ0.91 for cerclage) when compared with placebo and no cerclage, respectively ( Table 2 ). The number of patients who needed to be treated with vaginal progesterone rather than with placebo to prevent either 1 case of preterm birth at Ͻ32 weeks of gestation or 1 case of composite perinatal morbidity/mortality was 7 (95% CI, 5Ϫ38 for preterm birth at Ͻ32 weeks of gestation and 5Ϫ69 for composite perinatal morbidity/mortality). The corresponding numbers needed to treat for cerclage were 10 (95% CI, 7Ϫ38) and 11 (95% CI, 7Ϫ45), respectively.
Infants whose mothers received vaginal progesterone had a significantly lower risk of composite neonatal morbidity and admission to NICU than infants whose mothers had received placebo. Patients who were allocated to cerclage had a statistically significant reduction in the risk of preterm birth at Ͻ37, Ͻ35, and Ͻ28 weeks of gestation and a birthweight of Ͻ1500 g when compared with those who were allocated to no cerclage.
Indirect comparison
Adjusted indirect comparison metaanalyses showed that, compared with Occurrence of any of the following events: respiratory distress syndrome, grade III/IV intraventricular hemorrhage, necrotizing enterocolitis, neonatal sepsis, or bronchopulmonary dysplasia.
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Reports of Major Impact www.AJOG.org cerclage, treatment with vaginal progesterone was associated with a nonsignificant 29% reduction in the risk of preterm birth at Ͻ32 weeks of gestation (RR, 0.71; 95% CI, 0.34Ϫ1.49) and a 33% nonsignificant decrease in the risk of composite perinatal morbidity and mortality (RR, 0.67; 95% CI, 0.29Ϫ 1.57). Adjusted indirect comparison between vaginal progesterone and cerclage indicated that there was no significant difference for any of the secondary outcome measures. Estimated RRs ranged from 0.28 for bronchopulmonary dysplasia to 1.79 for grade III/IV intraventricular hemorrhage, but all 95% CIs included 1. These results indicate that vaginal progesterone and cerclage are not significantly different in terms of efficacy for the reduction of the risk of preterm birth and adverse perinatal outcomes.
Sensitivity analysis
Vaginal progesterone and cerclage significantly decreased the risk of preterm birth at Ͻ32 and Ͻ35 weeks of gestation in a sensitivity analysis that excluded both patients who received progestogens in trials that evaluated cerclage and those in whom a cerclage was placed in trials that evaluated vaginal progesterone ( Table 3 ). Cervical cerclage, compared with no intervention, was associated with a reduction in the rate of preterm birth at Ͻ37 weeks of gestation and perinatal mortality; however, indirect comparisons between vaginal progesterone and cerclage indicate that there were no significant differences between the 2 interventions. Sensitivity analyses based on trial quality were not performed because all trials were considered at low risk for biases.
There was low statistical heterogeneity in all but 2 metaanalyses (admission to NICU and birthweight Ͻ2500 g in comparison of cerclage vs no cerclage). Funnel plots showed no asymmetry, either visually or in terms of statistical significance.
COMMENT
Principal findings of the study
In women with a sonographic short cervix in the mid trimester, singleton gestation, and previous spontaneous preterm birth, (1) vaginal progesterone administration was associated with a significant 53% reduction in the risk of preterm birth at Ͻ32 weeks of gestation, a 57% decrease in the risk of composite perinatal morbidity and mortality, and a significantly lower rate of composite neonatal morbidity and admission to NICU when compared with placebo; (2) the placement of a cervical cerclage showed a significant 34% reduction in the risk of preterm birth at Ͻ32 weeks of gestation, a 36% decrease in the risk of composite perinatal morbidity and mortality, and a significantly lower rate of preterm birth at Ͻ37, Ͻ35, and Ͻ28 weeks of gestation and a birthweight of Ͻ2500 g when compared with no cerclage; and (3) there were no significant differences between the efficacy of vaginal progesterone and cerclage in the prevention of preterm birth or adverse perinatal outcomes. These findings were consistent with sensitivity analyses in which patients who received progestogens (eg, 17␣-hydroxyprogesterone caproate or vaginal progesterone), and cerclage were excluded.
Strengths and limitations of the study
Strengths of the study include (1) use of the most rigorous methodology for performing an indirect comparison metaanalysis of randomized controlled trials. Specifically, we applied the best available method to undertake the indirect comparisons, assessed the assumption of similarity of treatment effects using sensitivity analyses, evaluated statistical homogeneity, and reported the results following the recommended guidelines for this type of study; (2) indirect comparisons were performed by using data obtained from IPD metaanalyses 105,177 of 2 direct comparisons; (3) the access to data from individual patients enabled a more rigorous analysis from what is possible with published data; (4) a broad and deep literature search was performed to identify relevant studies; (5) the high methodologic quality of the majority of trials included in the review; (6) all patients included in the review had a cervical length Ͻ25 mm at or before 25 weeks of gestation, singleton gestation, and 
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Reports of Major Impact previous spontaneous preterm birth at less than 37 weeks of gestation; (7) the remarkable similar rates of preterm birth and adverse perinatal outcomes found in control groups of trials that evaluated vaginal progesterone and cerclage (Table  2 ) making more homogeneous the common comparator placebo/no cerclage in indirect metaanalyses; (8) the evidence of clinical and statistical homogeneity for most of the outcomes evaluated; (9) the sensitivity analysis, by excluding patients who received both progesterone and cerclage, was consistent with (and thus supportive of) our overall findings; and (10) the symmetric funnel plots suggesting absence of publication and related biases in our metaanalyses.
There are some potential limitations of our study. In recent years, the adjusted indirect comparison method has been used in health care decision-making to compare competing treatments in the absence of direct evidence about their relative effectiveness. The largest evaluation of the consistency between direct and indirect comparisons of trials found that there was a statistically significant inconsistency in 16 of 112 comparisons (14%), which may be more common with subjectively assessed outcomes, comparisons that include a lower number of trials in the analyses, and with statistically significant results from either direct or indirect comparisons.
232 A recent simulation study reported that indirect comparisons may be underpowered to determine treatment differences, particularly when there is a moderate-tolarge between-study degree of heterogeneity. 233 In addition, the risk of overestimation could be high when the indirect comparison of interest relies on just 1 trial for 1 of the 2 direct comparisons. However, virtually all outcome measures that were included in our study were assessed objectively, and most of the direct metaanalyses had a low degree of statistical heterogeneity. Moreover, the comparisons of cerclage vs no cerclage and vaginal progesterone vs placebo relied mainly on 2 trials each (Owen et al 174 Another potential limitation of this indirect metaanalysis was that 20% of women in the control group of trials that evaluated cervical cerclage received 17␣-hydroxyprogesterone caproate compared with none in the control group of trials that evaluated vaginal progesterone. This difference could potentially mean that the control groups, which were used as the common comparator, are not similar. Nevertheless, sensitivity analyses that were performed by excluding these patients showed no significant differences in the results that were obtained with overall metaanalyses. In addition, there is no evidence that 17␣-hydroxyprogesterone caproate can decrease the risk of preterm birth in women with a short cervix. 234 Given the apparent equivalence in efficacy between vaginal progesterone and cerclage, differences in adverse effects are key variables that clinicians and patients with a singleton pregnancy and a previous spontaneous preterm birth should consider when selecting an optimal treatment for a sonographic short cervix in the mid trimester. The IPD metaanalysis by Romero et al 105 showed that rates of maternal adverse effects, discontinuation of treatment because of adverse effects, and congenital anomalies did not differ significantly between the vaginal progesterone and placebo groups. The IPD metaanalysis by Berghella et al, 177 which evaluated cerclage vs no cerclage, did not provide data on adverse events, but the trial by Owen et al, 174 which contributed 60% of patients to that metaanalysis, reported that surgical and anesthetic complications that were associated with cerclage placement were uncommon. Nonetheless, a recently updated Cochrane review that assessed the use of cerclage in women with a singleton gestation who were at high risk of pregnancy loss found that, compared with no treatment, cerclage was associated with a statistically significant increased risk of maternal fever (RR, 2.39; 95% CI, 1.35Ϫ4.23) and cesarean delivery (RR, 1.19; 95% CI, 1.01Ϫ1.40). 235 The authors of that review speculated that the higher rates of cesarean delivery that were associated with cerclage could be due to biased diagnosis of failed induction or failure to progress in labor when clinicians knew that a woman had a cerclage earlier in pregnancy.
Implications for practice
The optimal method to compare the efficacy and safety of vaginal progesterone and cerclage in women with a sonographic short cervix in the mid trimester, singleton gestation, and previous spontaneous preterm is by a direct comparison with a randomized controlled clinical trial. It is unknown whether such a trial will be forthcoming in the near future. We have performed a sample size calculation to estimate the number of patients who would be required to conduct such a trial. Assuming a reduction in the frequency of preterm birth at Ͻ32 weeks of gestation from 19.2% in the cerclage group to 12.0% in the vaginal progesterone group, 800 patients (400 per group) would be required for this study to have an 80% power with an alpha of 0.05. In the absence of such a trial, we believe that the findings of the current study provide the best available evidence to counsel patients and inform physicians at this time.
Currently, the American College of Obstetricians and Gynecologists recommends the administration of 17␣-hydroxyprogesterone caproate for the prevention of preterm birth in women with a history of a spontaneous singleton preterm birth at Ͻ37 weeks of gestation. 236 Thus far, there are no randomized controlled trials that have compared 17␣-hydroxyprogesterone caproate vs placebo, 17␣-hydroxyprogesterone caproate vs vaginal progesterone, or 17␣-hydroxyprogesterone caproate plus cerclage vs cerclage alone or 17␣-hydroxyprogesterone caproate alone in women with a short cervix, singleton gestation, and previous spontaneous preterm birth for the prevention of preterm birth. A recently published secondary analysis of the trial by Owen et al 174 evaluated the efficacy of cerclage vs no cerclage in patients with a singleton gestation and previous spontaneous preterm birth who developed a short cervix (Ͻ25 mm) in the second trimester while receiving 17␣-hydroxyprogesterone caproate. 237 Of the 99 women who received 17␣-hydroxyprogesterone Reports of Major Impact www.AJOG.org caproate, 47 were allocated to have a cerclage, and 52 were allocated to the group who were treated without cerclage. The rates of preterm birth at Ͻ32, Ͻ28, Ͻ35, and Ͻ37 weeks of gestation among women who received 17␣-hydroxyprogesterone caproate and a cerclage were 17%, 9%, 30%, and 49%, respectively. The corresponding rates among women who received 17␣-hydroxyprogesterone caproate in the no cerclage group were 21%, 15%, 38%, and 60%, respectively. These outcome measures for preterm birth were not significantly different between the cerclage and no cerclage groups. The authors concluded that cerclage does not offer additional benefit for the prevention of preterm birth in women with a singleton gestation and a cervical length of Ͻ25 mm who are receiving 17␣-hydroxyprogesterone caproate because of a previous preterm birth.
In our sensitivity analysis reported herein, we found that the frequency of preterm birth at Ͻ32, Ͻ28, Ͻ35, and Ͻ37 weeks of gestation in women with a singleton gestation, previous preterm birth, and a short cervix who received vaginal progesterone was 11%, 7%, 24%, and 44%, respectively. These data suggest that vaginal progesterone is at least similar in efficacy to the combination of 17␣-hydroxyprogesterone caproate and cerclage in the prevention of preterm birth in women with a singleton gestation, previous spontaneous preterm birth, and a cervical length of Ͻ25 mm. Recently, a randomized clinical trial reported that 17␣-hydroxyprogesterone caproate did not reduce the risk of preterm birth at Ͻ32, Ͻ35, and Ͻ37 weeks of gestation when compared with placebo in nulliparous women with a short cervix (Ͻ30 mm). 234 In addition, subgroup analyses did not demonstrate a benefit from 17␣-hydroxyprogesterone caproate administration to women with a cervical length of Ͻ15 mm or 10-20 mm. Therefore, based on the totality of the current available evidence, we propose that women with a singleton pregnancy who have a history of singleton spontaneous preterm birth and have begun treatment with 17␣-hydroxyprogesterone caproate between 16 and 20 weeks of gestation be followed with serial cervical length measurements using transvaginal sonography beginning at approximately 18 weeks and continuing every 2 weeks until 23 6/7 weeks. If cervical length is Ͻ25 mm, vaginal progesterone should be offered to the patient because this intervention has been proven to be effective in women with a short cervix and a history of preterm birth. If cervical length is 25-30 mm, these patients could be followed with additional ultrasound examinations because they may still benefit from vaginal progesterone. There is no evidence to support the continued administration of 17␣-hydroxyprogesterone caproate in patients with a short cervix if vaginal progesterone is used. This approach would address the safety concerns that have been outlined by the Food and Drug Administration in the package insert of the commercially available form of 17␣-hydroxyprogesterone caproate (http://www.accessdata.fda.gov/drugsatfda_ docs/label/2011/021945s000lbl.pdf) and the lack of evidence that this synthetic progestin would be effective if the patient is already receiving vaginal progesterone because of a history of preterm birth and a cervix of Ͻ25 mm.
The key finding of this study is that vaginal progesterone and cervical cerclage have similar efficacy for the prevention of preterm birth and adverse perinatal outcomes in patients with a short cervix and a history of preterm birth. Given similar efficacy, therapeutic decision-making can be informed by reports about adverse events and cost-effectiveness of the interventions, as well as the patient and physician's preferences.
The current recommendation that patients with a short cervix and a history of preterm birth should be treated with cervical cerclage must be revisited in light of the results of the present study. Medical treatment with vaginal progesterone can decrease the risks that are associated with anesthesia and a surgical procedure; therefore, it is important to disclose the availability of a non-surgical therapeutic choice to patients with a history of preterm birth and a short cervix.
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